Cadrenal Therapeutics, Inc. (CVKD)Healthcare | Biotechnology | Ponte Vedra, United States | NasdaqCM
5.25 USD
+0.03
(0.575%)
⇧
(April 20, 2026, 4 p.m.
EDT)
Short-term: ★★★★☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:23 a.m. EDT
CVKD offers a compelling high-risk short-term momentum play (rating 4) fueled by analyst price targets averaging 27.67 (a 42% upside from current price) and recent volume surges, but it is an absolute avoidance candidate for long-term investors (rating 0) given its massive operating cash burn, negative earnings, and lack of dividend capacity. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.195849 |
| AutoETS | 0.197450 |
| AutoTheta | 0.197573 |
| MSTL | 0.210254 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 53% |
| H-stat | 3.08 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.182 |
| Excess Kurtosis | -1.22 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 13,160,789 |
| Forward P/E | -1.34 |
| Beta | 1.55 |
| Website | https://www.cadrenal.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.6863799 |
| Address1 | 822 A1A North |
| Address2 | Suite 306 |
| All Time High | 101.25 |
| All Time Low | 4.21 |
| Ask | 4.88 |
| Ask Size | 1 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 47,740 |
| Average Daily Volume3 Month | 49,204 |
| Average Volume | 49,204 |
| Average Volume10Days | 47,740 |
| Beta | 1.554 |
| Bid | 5.51 |
| Bid Size | 1 |
| Book Value | 1.171 |
| City | Ponte Vedra |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.25 |
| Current Ratio | 2.72 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 5.4415 |
| Day Low | 5.0145 |
| Display Name | Cadrenal Therapeutics |
| Earnings Timestamp End | 1,755,777,600 |
| Earnings Timestamp Start | 1,754,564,340 |
| Ebitda | -13,454,303 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.68 |
| Enterprise Value | 9,153,000 |
| Eps Current Year | -5.875 |
| Eps Forward | -3.91 |
| Eps Trailing Twelve Months | -6.64 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 6.256 |
| Fifty Day Average Change | -1.006 |
| Fifty Day Average Change Percent | -0.16080563 |
| Fifty Two Week Change Percent | -68.63799 |
| Fifty Two Week High | 17.5 |
| Fifty Two Week High Change | -12.25 |
| Fifty Two Week High Change Percent | -0.7 |
| Fifty Two Week Low | 4.21 |
| Fifty Two Week Low Change | 1.04 |
| Fifty Two Week Low Change Percent | 0.24703087 |
| Fifty Two Week Range | 4.21 - 17.5 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,674,225,000,000 |
| Float Shares | 1,983,795 |
| Forward Eps | -3.91 |
| Forward P E | -1.342711 |
| Free Cashflow | -7,784,269 |
| Full Exchange Name | NasdaqCM |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.20864001 |
| Held Percent Institutions | 0.0806 |
| Implied Shares Outstanding | 2,506,817 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,023-01-20 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,724,112,000 |
| Last Split Factor | 1:15 |
| Long Business Summary | Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions. The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida. |
| Long Name | Cadrenal Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 13,160,789 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_1793167154 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -13,237,362 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 13,160,789 |
| Number Of Analyst Opinions | 3 |
| Open | 5.22 |
| Operating Cashflow | -12,601,666 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 904 300 0701 |
| Pre Market Change | 0.19000006 |
| Pre Market Change Percent | 3.6190486 |
| Pre Market Price | 5.44 |
| Pre Market Time | 1,776,768,306 |
| Previous Close | 5.22 |
| Price Eps Current Year | -0.89361703 |
| Price Hint | 2 |
| Price To Book | 4.4833474 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.527 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 0.03000021 |
| Regular Market Change Percent | 0.5747167 |
| Regular Market Day High | 5.4415 |
| Regular Market Day Low | 5.0145 |
| Regular Market Day Range | 5.0145 - 5.4415 |
| Regular Market Open | 5.22 |
| Regular Market Previous Close | 5.22 |
| Regular Market Price | 5.25 |
| Regular Market Time | 1,776,715,200 |
| Regular Market Volume | 50,699 |
| Return On Assets | -1.16444 |
| Return On Equity | -2.6010902 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 2,506,817 |
| Shares Percent Shares Out | 0.0117 |
| Shares Short | 29,406 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 110,378 |
| Short Name | Cadrenal Therapeutics, Inc. |
| Short Percent Of Float | 0.014400001 |
| Short Ratio | 0.61 |
| Source Interval | 15 |
| State | FL |
| Symbol | CVKD |
| Target High Price | 45.0 |
| Target Low Price | 13.0 |
| Target Mean Price | 27.66667 |
| Target Median Price | 25.0 |
| Total Cash | 4,007,789 |
| Total Cash Per Share | 1.599 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -6.64 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 9.91168 |
| Two Hundred Day Average Change | -4.66168 |
| Two Hundred Day Average Change Percent | -0.4703219 |
| Type Disp | Equity |
| Volume | 50,699 |
| Website | https://www.cadrenal.com |
| Zip | 32,082 |